Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Fineline Cube Apr 10, 2026
Company Deals

Oricell Therapeutics Secures $110M+ Pre-IPO Round to Advance First-in-Class CAR-T for Liver Cancer

Fineline Cube Apr 10, 2026
Company Deals

IntuitiveFosun Partners with Sinopharm CDMC to Advance Surgical Robotics Adoption in China

Fineline Cube Apr 10, 2026
Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Fineline Cube Apr 10, 2026
Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Fineline Cube Apr 10, 2026
Company

Novo Nordisk to Invest RMB 400M in Shanghai at CIIE

Fineline Cube Nov 7, 2022

Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...

Company Drug

Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection

Fineline Cube Nov 7, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...

Company Drug

Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA

Fineline Cube Nov 7, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...

Company Drug

Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study

Fineline Cube Nov 4, 2022

China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...

Company Deals

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Policy / Regulatory

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Company Drug

Sinovac’s Varicella Vaccine Receives WHO Pre-Qualification

Fineline Cube Nov 4, 2022

China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...

Company Drug

Reforgene Medicine RM-001 Thalassemia Gene Editing

Fineline Cube Nov 4, 2022

China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...

Company Drug

Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine

Fineline Cube Nov 4, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...

Company Drug

Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19

Fineline Cube Nov 4, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized,...

Company

Bloomage Biotech CEO Investigated Over Discounted Share Sales

Fineline Cube Nov 4, 2022

The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao...

Policy / Regulatory

NMPA Proposes ‘Drug Online Sales Blacklist’ for Public Feedback

Fineline Cube Nov 4, 2022

The National Medical Products Administration (NMPA) has released a draft proposal for a “Drug Online...

Company Drug

Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH

Fineline Cube Nov 4, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...

Company Drug

Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma

Fineline Cube Nov 4, 2022

China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...

Company Drug

Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials

Fineline Cube Nov 4, 2022

China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy,...

Company Deals

Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products

Fineline Cube Nov 4, 2022

Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology...

Company Deals

Yaguo Technology Secures Series A+ Funding for Airway Management Devices

Fineline Cube Nov 4, 2022

Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...

Company Deals

Novatim Immune Therapeutics Raises RMB 500M in First Financing Round

Fineline Cube Nov 4, 2022

China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...

Company Deals

Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round

Fineline Cube Nov 4, 2022

Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...

Company Drug

Akeso Biopharma Completes Enrollment for AK112 Phase III Study

Fineline Cube Nov 4, 2022

China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...

Posts pagination

1 … 588 589 590 … 648

Recent updates

  • C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology
  • Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis
  • Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K
  • Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia
  • BeOne Medicines Secures NMPA Conditional Approval for Imdelltra (Tarlatamab) in Heavily Pretreated Small Cell Lung Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Company Drug

Lynk Pharmaceuticals’ JAK1 Inhibitor Zemprocitinib Enters NMPA Review for Atopic Dermatitis

Company Deals

Thermo Fisher Scientific Partners with Singapore’s PRECISE to Power Landmark Proteomics Study PRECISE-SG100K

Company Drug

Shanghai Ark Bio Advances AK0406, a Next-Gen Long-Acting Influenza ADFC, into Phase I Trial in Australia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.